Connect Biopharma Holdings Ltd. (CNTB)
0.80
-0.04
(-4.24%)
USD |
NASDAQ |
Oct 30, 16:00
0.80
0.00 (0.00%)
After-Hours: 19:56
Connect Biopharma Holdings Enterprise Value : 21.72M for Oct. 29, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 29, 2026 | 21.72M |
| October 28, 2026 | 22.34M |
| October 27, 2026 | 22.17M |
| October 26, 2026 | 22.57M |
| October 23, 2026 | 17.38M |
| October 22, 2026 | 17.10M |
| October 21, 2026 | 19.37M |
| October 20, 2026 | 24.23M |
| October 19, 2026 | 25.77M |
| October 16, 2026 | 26.18M |
| October 15, 2026 | 26.18M |
| October 14, 2026 | 26.35M |
| October 13, 2026 | 26.97M |
| October 12, 2026 | 26.15M |
| October 09, 2026 | 23.90M |
| October 08, 2026 | 24.57M |
| October 07, 2026 | 28.60M |
| October 06, 2026 | 26.13M |
| October 05, 2026 | 25.65M |
| October 02, 2026 | 27.49M |
| October 01, 2026 | 30.81M |
| September 30, 2026 | 38.38M |
| September 29, 2026 | 31.58M |
| September 28, 2026 | 37.12M |
| September 25, 2026 | 37.12M |
| Date | Value |
|---|---|
| September 24, 2026 | 38.38M |
| September 23, 2026 | 36.49M |
| September 22, 2026 | 45.62M |
| September 21, 2026 | 52.24M |
| September 18, 2026 | 49.72M |
| September 17, 2026 | 50.35M |
| September 16, 2026 | 47.20M |
| September 15, 2026 | 42.79M |
| September 14, 2026 | 77.74M |
| September 11, 2026 | 97.58M |
| September 10, 2026 | 98.84M |
| September 09, 2026 | 95.69M |
| September 08, 2026 | 89.39M |
| September 04, 2026 | 84.98M |
| September 03, 2026 | 90.65M |
| September 02, 2026 | 142.92M |
| September 01, 2026 | 117.73M |
| August 31, 2026 | 107.65M |
| August 28, 2026 | 109.54M |
| August 27, 2026 | 112.69M |
| August 26, 2026 | 115.84M |
| August 25, 2026 | 123.40M |
| August 24, 2026 | 113.95M |
| August 21, 2026 | 117.73M |
| August 20, 2026 | 112.69M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 8.312B |
| Oncolytics Biotech, Inc. | 49.64M |
| Sangamo Therapeutics, Inc. | 41.42M |
| Sarepta Therapeutics, Inc. | 2.288B |
| Anixa Biosciences, Inc. | 99.17M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -17.28M |
| Revenue (Quarterly) | 2.768M |
| Total Expenses (Quarterly) | 20.05M |
| EPS Diluted (Quarterly) | -0.2749 |
| Profit Margin (Quarterly) | -624.4% |
| Earnings Yield | -149.5% |
| Normalized Earnings Yield | -149.51 |